

Angiotensin Therapeutics is a privately held biopharmaceutical company focused on developing breakthrough therapies for Kidney Disease, including two orphan diseases, COVID 19 and other Coronavirus that use ACE2C as the entry receptor.

Our main biologics are short variants of a natural enzyme called **Angiotensin Converting Enzyme II (ACE2)** developed to treat kidney diseases. One of our ACE2 variants has been modified to increase the **duration** of action from hours to days which makes it much more suitable therapeutically. The potential therapeutic applications for this and other variants are **COVID-19** as ongoing preclinical studies show promise. COVID-19 has devastated the world today and has very limited therapeutic options.

We are working in collaboration with established investigators at Northwestern University Feinberg School to drive the execution of our development plan. This research is based on the laboratory work of well-known nephrologist, Dr. Daniel Battle and the application of a biologic variant of an enzyme designed for better pharmacodynamics and therapeutic benefits. We are uniquely prepared with the medical professionals and scientists to bring cutting edge treatments to the mainstream. Our mission is to develop lifesaving treatments.

Compelling Investment Opportunity in Initial Seed Round

- **Applying new biologically similar molecule for new therapeutic applications to an endogenous variant with a known and established safety profile**
- **Addressing huge unmet therapeutic needs in COVID 19 and Kidney Disease**
- **Potential focused markets in multi-billion dollar range**
- **De-risked development program with lead molecule safe as native molecule with a limited therapeutic window is in clinical trials**
- **Strong, long-life IP (licensed from Northwestern University Feinberg School of Medicine)**
- **Rapidly advancing to clinical validation in these new therapeutic indications**
 - **Straightforward manufacturing process needing to scale under cGMP oversight**
 - **Toxicology experiments likely minimal risk as active coding consistent with endogenous biologic**
- **Preclinical demonstration in relevant models**
- **Established academic collaborations with virology laboratories**
- **Experienced management team with scientific, drug development and capital market experience**
- **Major non-dilutive funding programs are accessible**
- **Short timelines to development partnerships**
- **Low seed valuation and managed capital gets to significant accretive clinical trials stage**

Minimal Capital Investment to Achieve Multiple Significant Value Inflection Points